Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis

Cellular Diagnosis, Chronic Lymphocytic Leukemia Clinical Trial

Official title:

Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03380299
• Other study ID #: 1700258
• Status: Active, not recruiting
• Phase: N/A
• First received: December 8, 2017
• Last updated: December 15, 2017
• Start date: July 14, 2016
• Est. completion date: December 14, 2018

Study information

• Verified date: December 2017
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation

Description:

Chronic lymphocytic leukemia (CLL) is the most common type of chronic leukemia, accounting for approximately 40% of all leukemia's and mainly affecting older individuals. As it has a highly variable clinical course, identification of molecular and biological prognostic markers has provided new insights into the risk stratification of patients with CLL .

The interactions of chronic lymphocytic leukemia cells with the microenvironment in secondary lymphoid tissues and the bone marrow are known to promote CLL cell survival and proliferation . CD49d (one of biomarkers) is one of independent prognostic risk parameter in CLL with important roles in shaping these interactions.

CD49d also is one of independent prognostic risk parameters in CLL that predict adverse outcome and linked to processes involved in interaction with the vascular endothelium and/or migration into the extravascular compartments .

The cell-surface glycoprotein CD44 is involved in cell motility, cellular trafficking, and stem cell differentiation . It contributes to the phenotypic hallmarks of many cancers, such as invasiveness, self-renewal, and sustained survival. CD44 transmits both growth and apoptotic signals, a functional duality that is also observed in hematologic malignancies.

CD44 expression in CLL is mediated by the tumor microenvironment. As a coreceptor, CD44 promotes leukemogenesis by regulating stimuli of MCL1 expression. Moreover, CD44 can be addressed therapeutically in CLL by specific antibodies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 2
• Est. completion date: December 14, 2018
• Est. primary completion date: September 14, 2018
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All patients are newly diagnosed as CLL

Exclusion Criteria:

• : patients with associated malignancies

Related Conditions & MeSH terms

• Cellular Diagnosis, Chronic Lymphocytic Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Lymphoid

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To what extent the identi?cation of molecular and biological prognostic markers has provided new insights into the risk strati?cation of patients with CLL .	detecting membrane expression of CD49d and CD 44 and thier role in prognosis of CLL patients.	1 YEAR